Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
Trevi Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on November 13, 2025. The filing announces the financial results for the quarter ended September 30, 2025. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol TRVI.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the referenced press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended September 30, 2025, by reviewing Exhibit 99.1 (Press Release) as the 8-K text itself contains no numerical data.
- Confirm the company's cash position and runway, as these are critical for a clinical-stage biopharmaceutical company but are not listed in this summary document.
- Review the press release for any updates on clinical trial progress or regulatory milestones that may accompany the financial announcement.
- Note that the financial information in this filing is furnished and not subject to the liabilities of Section 18 of the Exchange Act.